Martin Samuel Bates

Average Profitability
500.67%
Insider Buys Quantity
1
Insider Buys Sum
$29,737.50
Insider Sells Quantity
6
Insider Sells Sum
$3.26M

Insider Activity of Martin Samuel Bates

According to the SEC Form 4 filings, Martin Samuel Bates, being in a position of

  1. SVP AND CFO at Celldex Therapeutics, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 52172 shares for $1.8M,
    over all time since 2020-06-09, has bought 9750 shares for $29,738, and sold 88171 share for $3.26M.

The largest purchase of all time was on 2020-06-09 and amounted to 9750 shares of Celldex Therapeutics, Inc. for $29,738.

The largest sale of all time was on 2024-05-30 and amounted to 35000 shares of Celldex Therapeutics, Inc. for $1.19M.

Biography of Martin Samuel Bates

No biography is available at this moment.

2024-06-14SaleCelldex Therapeutics, Inc.
CLDX
SVP AND CFO
17,172
0.0259%
$35.42$608,315+2.94%
2024-05-30SaleCelldex Therapeutics, Inc.
CLDX
SVP AND CFO
35,000
0.0538%
$34.05$1.19M+4.94%
2022-08-11SaleCelldex Therapeutics, Inc.
CLDX
SVP AND CFO
14,261
0.0324%
$36.76$524,304+1.9%
2021-12-23SaleCelldex Therapeutics, Inc.
CLDX
SVP and CFO
9,500
0.0203%
$42.00$399,000-25.17%
2021-11-15SaleCelldex Therapeutics, Inc.
CLDX
SVP and CFO
9,500
0.0206%
$43.57$413,883-26.92%
2021-08-10SaleCelldex Therapeutics, Inc.
CLDX
SVP and CFO
2,738
0.0059%
$45.25$123,895-26.24%
2020-06-09PurchaseCelldex Therapeutics, Inc.
CLDX
SVP and CFO
9,750
0.045%
$3.05$29,738+500.67%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.